Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Intern Med ; 45(7): 453-5, 2006.
Article in English | MEDLINE | ID: mdl-16679700

ABSTRACT

OBJECTIVE: To determine the effective dose of cabergoline in Japanese patients with restless legs syndrome (RLS). METHODS: Six cases of idiopathic RLS and three of RLS with Parkinson disease (PD) participated in an open clinical preliminary trial. All cases were diagnosed based on the clinical criteria of the International RLS Study Group. Three RLS cases (1.3%) were detected out of 229 consecutive cases with PD. RLS severity was evaluated with International RLS Study Group (IRLSSG) Rating Scale Version 2.2 before and one year after the treatment with cabergoline. RESULTS: For 6 idiopathic RLS patients, the IRLSSG questionnaire scores improved from 25.5+/-3.7 to 10.7+/-8.9 (p=0.028, Wilcoxon test) with 1 mg of daily cabergoline at the endpoint. For 3 RLS cases with PD, the score was 21.7+/-3.7 before the treatment, and RLS symptoms completely disappeared with 1 mg of cabergoline. One of RLS cases with PD required additional cabergoline later because of parkinsonism. No adverse event with cabergoline was reported in this study. CONCLUSION: One mg of daily cabergoline is effective in some Japanese patients of RLS.


Subject(s)
Dopamine Agonists/therapeutic use , Ergolines/therapeutic use , Restless Legs Syndrome/drug therapy , Aged , Aged, 80 and over , Cabergoline , Female , Humans , Male , Middle Aged , Treatment Outcome
2.
Intern Med ; 45(1): 1-4, 2006.
Article in English | MEDLINE | ID: mdl-16467596

ABSTRACT

OBJECTIVE: Treatment with a free radical scavenger could be a new option for ischemic brain attack, however, little is known about the alteration of oxidative stress markers induced by edaravone, a novel free radical scavenger, in human ischemic brain attack. METHODS: We investigated the effects of edaravone on the oxidative stress markers in patients with ischemic brain attack. Twenty-one patients with ischemic brain attack and 19 controls were enrolled in this study. Blood samples were obtained just before and soon after the first administration of edaravone (30 mg) or ozagrel (40 mg). Intracellular reactive oxygen species of neutrophils were measured using 6-carboxy-2', 7'-dichlorodihydrofluorescin diacetate and a fluorescence-activated cell sorter. Superoxide from neutrophils, induced by phorbol myristate acetate (PMA), was determined by luminol-amplified chemiluminescence assay. RESULTS: Treatment with 30 mg of edaravone significantly decreased the intracellular reactive oxygen species (ROS) of neutrophils (Wilcoxon test, p=0.0001) and PMA-induced superoxide produced by neutrophils (Wilcoxon test, p=0.001). Ozagrel did not alter the intracellular ROS or superoxide production of neutrophils. CONCLUSION: Reduction of intracellular ROS and suppression of superoxide production in neutrophils provide a potential explanation for the clinical efficacy of edaravone in patients with ischemic brain attack.


Subject(s)
Antipyrine/analogs & derivatives , Brain Ischemia/blood , Brain Ischemia/drug therapy , Free Radical Scavengers/therapeutic use , Free Radicals/metabolism , Neutrophils/drug effects , Neutrophils/metabolism , Oxidative Stress/drug effects , Aged , Aged, 80 and over , Antipyrine/therapeutic use , Edaravone , Female , Humans , Male , Middle Aged
3.
Rinsho Shinkeigaku ; 42(9): 878-80, 2002 Sep.
Article in Japanese | MEDLINE | ID: mdl-12710089

ABSTRACT

We reported a 62-year-old woman had sensorimotor neuropathy with small cell lung carcinoma (SCLC) and anti-GM1 antibody. She was admitted with several months history of progressive numbness, walking disturbance and anorexia. Neurologic examination revealed severe numbness and deep sensory disturbance of extremities and body, and mild weakness of distal extremities. Deep tendon reflexes were absent. Her limbs were ataxic. Nerve conduction studies showed no sensory evoked responses. CSF protein was elevated. Sural nerve biopsy revealed severe loss of myelinated fibers and perivascular mononuclear cells surrounding the perineurial vessel. Vasculitic neuropathy was diagnosed, and prednisolone was started, with no benefit. In the clinical course, she developed cough attacks and was found the lymphnode swelling in the mediastinum and supraclavicular fossa, which was diagnosed SCLC. Although anti-Hu antibody were not detected, anti-GM1 antibody was positive. She was treated with intravenous immunoglobulin, with transient improvement. The rare case of the paraneoplastic peripheral neuropathy with SCLC and anti-GM1 antibody was reported.


Subject(s)
Autoantibodies/analysis , Carcinoma, Small Cell/immunology , G(M1) Ganglioside/immunology , Lung Neoplasms/immunology , Motor Neurons , Neurons, Afferent , Paraneoplastic Polyneuropathy/immunology , Autoimmunity , Fatal Outcome , Female , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...